In Health Care, Alexion Pharmaceuticals’ (NASDAQ:ALXN) weakness reflected investor concern about a change in senior management and disappointment that the Food and Drug Administration did not grant priority review for the company’s drug Soliris as a treatment for an ultra-rare form of myasthenia gravis. Soliris is already approved to treat two rare, genetic, and potentially life-threatening blood disorders. Other approved drugs target a disease caused by genetic mutations and an ultra-rare metabolic disorder.
From Spiros Segalas (Trades, Portfolio)' Harbor Capital Appreciation Fund Managers' second quarter 2017 commentary.
